Patel Chem Specialities IPO subscribed 63.28 times on Day 3. Check GMP and other details
K N Mishra
29/Jul/2025
What's covered under the Article:
-
Patel Chem Specialities IPO worth ₹58.8 crore opens July 25-29 2025 with share price band ₹82 to ₹84 and listing on BSE SME expected August 1, 2025.
-
IPO subscribed 9.67 times on second day with ₹16.69 crore raised from anchor investors and 13% Grey Market Premium signaling healthy listing gains.
-
Patel Chem Specialities manufactures pharmaceutical excipients with steady financial growth and experienced promoters Bhupesh and Anshu Patel.
Patel Chem Specialities Limited is a trusted leader in manufacturing high-quality pharmaceutical excipients, which are critical raw materials for drug formulation. The company boasts decades of experience and specializes in producing a wide range of excipients including Sodium Carboxy Methyl Cellulose (Sodium CMC), Sodium Starch Glycolate (SSG), Croscarmellose Sodium (CCS), Calcium CMC, Magnesium Stearate, Pregelatinised Starch, and also produces a key API intermediate called Sodium Monochloroacetate.
IPO Details
Patel Chem Specialities has launched a Book Built Issue IPO amounting to ₹58.8 crore, consisting entirely of a Fresh Issue of 70 lakh shares. The subscription window is from July 25, 2025, to July 29, 2025. The allotment is expected to be finalized by July 30, 2025, with shares tentatively listed on the BSE SME platform on August 1, 2025.
-
Price Band: ₹82 to ₹84 per equity share
-
Market Capitalisation: ₹208.90 crore at the upper price band
-
Lot Size: 1,600 shares
-
Minimum Investment: Minimum 2 lots (3,200 shares) amounting to ₹2,68,800 for individual investors
Lead Managers, Registrar, and Market Maker
-
Book Running Lead Managers: CUMULATIVE CAPITAL PRIVATE LIMITED and UNISTONE CAPITAL PRIVATE LIMITED
-
Registrar: MUFG Intime India Private Limited
-
Market Maker: Globalworth Securities Limited
Subscription Status and Anchor Investors
As of 12:30 PM on July 28, 2025, the IPO was subscribed 9.67 times, indicating strong investor demand on the second day of the subscription period. The company raised ₹16.69 crore from anchor investors at ₹84 per share, allotting 19.87 lakh equity shares to anchor investors, signaling institutional confidence in the issue.
Grey Market Premium (GMP)
The Grey Market Premium for Patel Chem Specialities IPO is ₹11, translating to an approximate 13% premium over the upper price band, reflecting positive market expectations about listing gains. Investors should approach GMP figures with caution as they are unofficial and depend on unregulated demand-supply dynamics.
About Patel Chem Specialities
Patel Chem Specialities is a manufacturer of pharmaceutical excipients used as raw materials in drug formulation. Their product portfolio includes Sodium CMC, SSG, CCS, Calcium CMC, Magnesium Stearate, Pregelatinised Starch, and Sodium Monochloroacetate, a key API intermediate. The company’s products are crucial for pharmaceutical manufacturing, making them an integral part of the pharma supply chain.
The company’s leadership includes:
-
Bhupesh Patel (Managing Director): Over 30 years of experience in pharmaceuticals and nutraceuticals, driving manufacturing, product development, and marketing strategy.
-
Anshu Patel (Whole-Time Director): Holds a bachelor’s degree in Homoeopathic Medicine and Surgery, with over 10 years of experience, overseeing strategic planning and operational functions.
Financial Performance
-
Revenue from operations (₹ lakh):
-
FY23: 6,974.75
-
FY24: 8,271.61
-
FY25: 10,555.18
-
-
EBITDA (₹ lakh):
-
FY23: 582.64
-
FY24: 1,202.18
-
FY25: 1,573.02
-
-
Profit After Tax (₹ lakh):
-
FY23: 288.61
-
FY24: 765.62
-
FY25: 1,056.52
-
This steady rise in revenue, EBITDA, and profits over three years reflects strong operational growth and financial stability.
Key Financial Metrics
-
Pre-issue EPS: ₹6.10 (FY24)
-
Post-issue EPS: ₹4.25 (FY24)
-
Pre-issue P/E Ratio: 13.77x
-
Post-issue P/E Ratio: 19.77x
-
Industry P/E Ratio: 18x
-
ROCE: 36.26%
-
ROE: 29.85%
-
RoNW: 24.32%
These metrics indicate that the IPO is fairly priced relative to industry benchmarks.
Use of IPO Proceeds
The company intends to use the net proceeds primarily for:
-
₹43.15 crore for capital expenditure towards setting up a new manufacturing plant at Indrad, Mahesana, to produce Croscarmellose Sodium (CCS), Sodium Starch Glycolate (SSG) – Corn Starch and Potato Starch Base, and Calcium Carboxymethylcellulose (CMC).
-
General corporate purposes
Investment Outlook
With a strong product portfolio essential to the pharmaceutical industry, experienced leadership, and consistent financial growth, Patel Chem Specialities Limited offers a promising investment opportunity. The robust subscription and positive Grey Market Premium reflect market confidence, making it a potential candidate for listing gains.
How to Check Allotment Status
IPO allotment status will be available on or after July 30, 2025, on the registrar’s website:
-
Select Patel Chem Specialities Limited IPO
-
Enter application number, PAN, or DP Client ID
-
Submit details to check allotment status
Disclaimer:
This article is for educational and informational purposes only and does not constitute financial advice or an offer to buy or sell securities. Investors should conduct their own due diligence and consult financial advisors before investing. Securities investments are subject to market risks.
The Upcoming IPOs in this week and coming weeks are Highway Infrastructure, Flysbs Aviation, Part Electricals & Engineering, Jyoti Global Plast, M&B Engineering, Cash Ur Drive Marketing, Renol Polychem, Jyoti Global Plast, Takyon Networks, Mehul Colours, Sri Lotus Developers & Realty, Jyoti Global Plast, B.D. Industries (Pune), NSDL.
The Current active IPO are Aditya Infotech, Lakshmi India Finance, Kaytex Fabrics, Umiya Mobile, Repono, Shree Refrigerations, Sellowrap Industries, Shanti Gold International, Patel Chem Specialities.
Start your Stock Market Journey and Apply in IPO by Opening Free Demat Account in Choice Broking FinX.
Join our Trading with CA Abhay Telegram Channel for regular Stock Market Trading and Investment Calls by CA Abhay Varn - SEBI Registered Research Analyst.
Related News
Disclaimer
The information provided on this website is for educational and informational purposes only and should not be considered as financial advice, investment advice, or trading recommendations.
Trading in stocks, forex, commodities, cryptocurrencies, or any other financial instruments involves high risk and may not be suitable for all investors. Prices can fluctuate rapidly, and there is a possibility of losing part or all of your invested capital.
We do not guarantee any profits, returns, or outcomes from the use of our website, services, or tools. Past performance is not indicative of future results.You are solely responsible for your investment and trading decisions. Before making any financial commitment, it is strongly recommended to consult with a qualified financial advisor or do your own research.
By accessing or using this website, you acknowledge that you have read, understood, and agree to this disclaimer. The website owners, partners, or affiliates shall not be held liable for any direct or indirect loss or damage arising from the use of information, tools, or services provided here.